COMMUNIQUÉS West-GlobeNewswire

Rexahn Pharmaceuticals Presents Preliminary Safety and Efficacy Data From Ongoing Phase 2a Clinical Trial of RX-3117 in Combination With Abraxane® in Patients Newly Diagnosed With Metastatic Pancreatic Cancer

02/10/2018 - 14:00

Combination of RX-3117 and Abraxane Appears Safe and Well-Tolerated When Administered at the Recommended Phase 2 Dose of RX-3117 and the Maximal Labeled Dose of Abraxane Preliminary Efficacy was Observed With One [...]

Pieris Pharmaceuticals to Present Preclinical Data for 4-1BB/PD-L1 Bispecific PRS-344/ONC0055 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

02/10/2018 - 14:00

BOSTON, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for [...]

Cellectar Announces Overall Survival Exceeding 19 Months in Phase 1b Trial with CLR 131 in Relapsed/Refractory Multiple Myeloma

02/10/2018 - 14:00

MADISON, Wis., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of [...]

Melinta Therapeutics Publishes Complete Results from Phase III TANGO 2 Study of Vabomere™ (meropenem and vaborbactam)

02/10/2018 - 14:00

Vabomere monotherapy was associated with increased clinical cure, decreased mortality, and was well tolerated compared to best available therapy (BAT) - Data used by CMS in decision to grant a new technology add-on [...]

Immutep Announces Presentations at Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting

02/10/2018 - 14:00

SYDNEY, Australia, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune [...]

Major Cancer Journal Highlights Data From An Inovio-Sponsored Trial In Which A Patient Achieved Full Remission After Dosing With DNA Immunotherapy and Checkpoint Inhibitor

02/10/2018 - 14:00

Study results published in Clinical Cancer Research shows that DNA immunotherapy approach drove T cell infiltration in tumors PLYMOUTH MEETING, Pa., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ [...]

BioCorRx Provides BICX102 Grant Update

02/10/2018 - 13:51

ANAHEIM, CA, Oct. 02, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of advanced solutions in the treatment of substance use disorders, today provided [...]

Otonomy Announces OTIVIDEX™ Data Presentation at American Academy of Otolaryngology - Head and Neck Surgery Foundation Annual Meeting

02/10/2018 - 13:30

Positive Results from AVERTS-2 Phase 3 Clinical Trial will Support Submission for U.S. Registration and Provide Basis for Ongoing Additional Phase 3 Trial SAN DIEGO, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. ( [...]

Biogen Highlights at ECTRIMS 2018 Data on Its Industry-Leading Multiple Sclerosis Portfolio and a Range of Initiatives Aimed at Transforming Patient Care

02/10/2018 - 13:30

New research further supports the long-term efficacy and well-characterized safety of leading MS products N ovel data generation initiatives aim to improve outcomes and support the continued move toward precision [...]

Transactions in relation to share buyback program

02/10/2018 - 13:06

Acting under its share buyback authorization, the GN Store Nord Board of Directors initiated a share buyback program on May 2, 2018, in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on [...]

Assembly Biosciences Announces Oral Presentation at 2018 AASLD

02/10/2018 - 13:05

SAN FRANCISCO, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases [...]

Oncolytics Biotech® Announces a Publication Demonstrating That Intravenously Delivered Oncolytic Viruses Effectively Target Tumors Even in the Presence of Neutralizing Antibodies

02/10/2018 - 13:00

CALGARY, Alberta and SAN DIEGO, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus turning cold [...]

Helius Medical Technologies and HealthTech Connex Announce Alliance to Build Canadian Commercial Infrastructure

02/10/2018 - 13:00

NEWTOWN, Pa., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that the [...]

Amicus Therapeutics Announces Presentation and Poster at the 23rd International Congress of the World Muscle Society

02/10/2018 - 13:00

CRANBURY, N.J., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), today announced that an oral presentation and a poster highlighting its development program AT-GAA for Pompe disease will be included [...]

Vistin Pharma ASA : Prospectus Summary for transfer of listing from Oslo Axess to Oslo Børs

02/10/2018 - 12:30

Oslo, Norway, 2 October 2018 Reference is made to the announcement on 26 September 2018 regarding Oslo Børs' resolution to admit the shares in Vistin Pharma ASA to listing on Oslo Børs. Vistin Pharma ASA today published [...]

ChromaDex Appoints Yan Chu as Managing Director, Asia Pacific

02/10/2018 - 12:30

LOS ANGELES, Oct. 02, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today that it has appointed Yan Chu as Managing Director, Asia Pacific, effective today. Based in Singapore, Chu will lead the TRU [...]

Clementia Initiates Phase 1 Clinical Trial of Palovarotene Eye Drop Formulation in Healthy Volunteers

02/10/2018 - 12:30

Data from Study Expected in Q1 2019 MONTREAL, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare [...]

Clementia amorce un essai clinique de phase 1 portant sur une formulation de gouttes oculaires à base de palovarotène mené chez des volontaires sains

02/10/2018 - 12:30

Disponibilité prévue des données de l’étude : T1 2019 MONTRÉAL, 02 oct. 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ : CMTA), une société biopharmaceutique au stade clinique proposant des traitements [...]

Addressing social and cultural drivers of type 2 diabetes is key to its treatment and prevention

02/10/2018 - 12:01

Berlin, Germany, 2 October 2018 - New research shows healthcare services and public health strategies aimed at reducing the burden of type 2 diabetes may prove ineffective, unless they address social and cultural [...]